
Haemonetics Corporation
HAE
Updated: 22/09/2026, 16:38:48
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
No summaries found.
- Share price
- $109.34
- Market cap
- $4.97B
- Exchange
- NYSE
- Currency
- USD
- CEO
- Christopher A. Simon
- Employees
- 3,009
- IPO date
- 10/05/1991
- Beta
- 0.543
- Last dividend
- $0.00
- Day range
- $108.65 – $109.95
- 52-week range
- $47.32 – $110.45
- 1-day performance
- 0.56%
- 1-year performance
- 131.07%
- Current drawdown (1Y)
- -1.00%
- CIK
- 0000313143
- CUSIP
- 405024100
- ISIN
- US4050241003
- Created
- 07/12/2025, 04:28:52
- Last update
- 22/09/2026, 16:38:48
Track Haemonetics Corporation with an AI analyst
See which prediction-market events move HAE, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
GlobeNewsWire • STOCK • 12/06/2026, 09:00:00
Haemonetics Corporation (HAE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 08/06/2026, 21:18:30
Haemonetics Updates Financial Reporting Segments
PRNewsWire • STOCK • 05/06/2026, 08:30:00
Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference
PRNewsWire • STOCK • 02/06/2026, 18:05:00
Investing in Haemonetics (HAE)? Don't Miss Assessing Its International Revenue Trends
Zacks Investment Research • STOCK • 22/05/2026, 12:15:55
Haemonetics Corporation (HAE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 12/05/2026, 15:20:51
HAE Stock Gains on Q4 Earnings & Revenue Beat, Gross Margin Cut
Zacks Investment Research • STOCK • 11/05/2026, 17:26:26
Haemonetics Q4 Earnings Call Highlights
MarketBeat • STOCK • 10/05/2026, 17:05:21
The London Company Small Cap Portfolio Q1 2026 Portfolio Review
Seeking Alpha • STOCK • 08/05/2026, 07:11:00
Haemonetics Corporation (HAE) Q4 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 08/05/2026, 04:41:17
Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates
Zacks Investment Research • STOCK • 07/05/2026, 10:10:17
Haemonetics to Present at Bank of America 2026 Healthcare Conference
PRNewsWire • STOCK • 05/05/2026, 08:00:00